Enzyme Replacement Therapy Medicines
Supply of Enzyme Replacement Therapy Medicines (a-d) to NHS Scotland: - NP92624(a) Laronidase 500units/5ml solution for infusion vials 1 vial (Aldurazyme®) - NP92624(b) Imiglucerase 400unit powder for solution for infusion vials 1 vial (Cerezyme®) - NP92624(c) Agalsidase beta 35mg powder for solution for infusion vials 1 vial (Fabrazyme®) - NP92624(c) Agalsidase beta 5mg powder for solution for infusion vials 1 vial (Fabrazyme®) - NP92624(d) Alglucosidase alfa 50mg powder for solution for infusion vials 1 vial (Myo...
Buyer
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Value
£12,437,853
Published
15 Aug 2024
Closes
15 Aug 2024
Procurement details
Source
Find a Tender
Region
Scotland
Procurement method
Limited
Category
Goods
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
33600000
Pharmaceutical products
Lots
Lot 1 Enzyme Replacement Therapy Medicines
£12,437,853
The Framework Agreement is for the supply of Enzyme Replacement Therapy Medicines (a-d: Aldurazyme®/ Cerezyme®/ Fabrazyme®/ Fabrazyme®/ Myozyme®) to NHS Scotland. The Authority has awarded this framework as a Single supplier framework agreement to one (1) Framework Participant.
Delivery: Scotland
Documents
No document metadata is available for this public record.
Contains public sector information licensed under the Open Government Licence v3.0.